Evaluating venetoclax and its potential in treatment-naïve acute myeloid leukemia

Venetoclax (ABT-199), a BH3-mimetic and selective BCL-2 inhibitor, was recently approved by the US Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML) in adult patients aged 75 years or older, or otherwise unable to tolerate intensive induction chemotherapy, in combi...

Descripción completa

Detalles Bibliográficos
Autores principales: Knight, Tristan, Edwards, Holly, Taub, Jeffrey W, Ge, Yubin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499443/
https://www.ncbi.nlm.nih.gov/pubmed/31118772
http://dx.doi.org/10.2147/CMAR.S180724

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499443/
https://www.ncbi.nlm.nih.gov/pubmed/31118772
http://dx.doi.org/10.2147/CMAR.S180724

Ejemplares similares